Blueprint Medicines says partner Genentech withdraws use of Gavreto for thyroid cancer
30/06/2023 11:26
June 30 (Reuters) - Blueprint Medicines BPMC.O said on Friday its partner Genentech Inc has withdrawn use of its cancer drug Gavreto for treating a type of thyroid cancer in patients aged 12 years and above. (Reporting by Raghav Mahobe in Bengaluru; Editing by Dhanya Ann Thoppil) ((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G